ArticleFuture virology2011
Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.
Article in Future virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Pooled it
- Antiviral and Cytoprotective Effect of Zinc (Yasad Bhasma) Based Nanoformulations Against Bovine Coronavirus.Indian journal of microbiology · 2024Article
- Subversion of autophagy machinery and organelle-specific autophagy by SARS-CoV-2 and coronaviruses.Autophagy · 2023Review
- COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Journal of infection and public health · 2023Review
- Tackling COVID-19 Using Antiviral Nanocoating's-Recent Progress and Future Challenges.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2023Review
- Antiviral Activity of Medicinal Plants against Human Coronavirus: a systematic scoping review of and experimentations.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Nanocoatings: Universal antiviral surface solution against COVID-19.Progress in organic coatings · 2022Review
- Processing and Quality Control of Masks: A Review.Polymers · 2022Review
- Recent advances and applications of polymeric materials in healthcare sector and COVID-19 management.Materials today. Proceedings · 2022Article
- Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.Journal of clinical laboratory analysis · 2021Article
- Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Therapeutic opportunities of edible antiviral plants for COVID-19.Molecular and cellular biochemistry · 2021Review
- The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.International immunopharmacology · 2021Review
- Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2.International nano letters · 2021Review
- Emerging Technologies for the Treatment of COVID-19.Advances in experimental medicine and biology · 2021Article
- Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2020Review
- Drug repurposing approach to fight COVID-19.Pharmacological reports : PR · 2020Review
- Curcumin, a traditional spice component, can hold the promise against COVID-19?European journal of pharmacology · 2020Review
- Severe Acute Respiratory Syndrome Coronavirus (SARS, SARS CoV).Disease-a-month : DM · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in early 2003 to cause a very severe acute respiratory syndrome, which eventually resulted in a 10% case-fatality rate. Owing to excellent public health measures that isolated focus cases and their contacts, and the use of supportive therapies, the epidemic was suppressed to the point that further cases have not appeared since 2005. However, despite intensive research since then (over 3500 publications), it remains an untreatable disease. The potential for re-emergence of the SARS-CoV or a similar virus with unknown but potentially serious consequences remains high. This is due in part to the extreme genetic variability of RNA viruses such as the coronaviruses, the many animal reservoirs that seem to be able host the SARS-CoV in which reassortment or recombination events could occur and the ability coronaviruses have to transmit relatively rapidly from species to species in a short period of time. Thus, it seems prudent to continue to explore and develop antiviral chemotherapies to treat SARS-CoV infections. To this end, the various efficacious anti-SARS-CoV therapies recently published from 2007 to 2010 are reviewed in this article. In addition, compounds that have been tested in various animal models and were found to reduce virus lung titers and/or were protective against death in lethal models of disease, or otherwise have been shown to ameliorate the effects of viral infection, are also reported.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.